Innovative laser system

Article

Schwind product profile.

SCHWIND has announced the addition of the new flagship system to the company's excimer laser portfolio, the SCHWIND AMARIS 1050RS.

This innovative laser system operates at a repetition rate of 1050 Hz, which enables an extremely short ablation time of just 1.3 seconds per dioptre (myopia, without astigmatism, 12.5 mm vertex distance and 6 mm optical zone). According to the company, this leads to greater safety and patient comfort.

Additionally, it is reported that this system shortens the length of exposure time for the corneal stroma, minimizing the risk of drying out. Also, the length of time that the patient is required to fixate on the green light is reduced. Further to this, the new system incorporates Intelligent Thermal Effect Control that protects the tissue from thermal damage.

The company states that another innovative feature of AMARIS 1050RS is the active 7 D eye tracking in space and time. This Latency-Free Tracking enables anticipation and pre-compensation of eye movements during the period between acquisition of the eyetracker image and triggering of the subsequent laser pulses - resulting in zero latency and greater safety.

Company name: SCHWIND eye-tech-solutions GmbH & Co. KG
Telephone: +49 (0) 60 27/5 08-164
E-mail: antje.splittdorf@eye-tech.netWebsite: www.eye-tech-solutions.com

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
© 2025 MJH Life Sciences

All rights reserved.